Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 27 August 1982:
Vol. 217. no. 4562, pp. 841 - 843
DOI: 10.1126/science.6808665
Prev | Table of Contents | Next

Articles

Science, Vol 217, Issue 4562, 841-843
Copyright © 1982 by American Association for the Advancement of Science

articles

Leukotriene D4: a potent coronary artery vasoconstrictor associated with impaired ventricular contraction

F Michelassi, L Landa, RD Hill, E Lowenstein, WD Watkins, AJ Petkau, and WM Zapol

Leukotriene D4 (2 c 10(-9) mole), injected into the left circumflex coronary artery of anesthetized sheep, produced profound coronary vasoconstriction and impaired regional ventricular wall motion. This cardiac effect was neither inhibited by prior treatment of the sheep with a cyclooxygenase inhibitor nor associated with thromboxane B2 release into the coronary sinus. Intravenous FPL 55712 completely abolished the coronary vasoconstriction of leukotriene D4, but a significant reduction of regional wall shortening persisted.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
International Union of Pharmacology XXXVII. Nomenclature for Leukotriene and Lipoxin Receptors.
C. Brink, S.-E. Dahlen, J. Drazen, J. F. Evans, D. W. P. Hay, S. Nicosia, C. N. Serhan, T. Shimizu, and T. Yokomizo (2003)
Pharmacol. Rev. 55, 195-227
   Abstract »    Full Text »    PDF »
Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis.
R. Spanbroek, R. Grabner, K. Lotzer, M. Hildner, A. Urbach, K. Ruhling, M. P. W. Moos, B. Kaiser, T. U. Cohnert, T. Wahlers, et al. (2003)
PNAS 100, 1238-1243
   Abstract »    Full Text »    PDF »
Monoclonal Anti-CD18 Antibody Prevents Transcellular Biosynthesis of Cysteinyl Leukotrienes In Vitro and In Vivo and Protects Against Leukotriene-Dependent Increase in Coronary Vascular Resistance and Myocardial Stiffness.
A. Sala, G. Rossoni, F. Berti, C. Buccellati, A. Bonazzi, J. Maclouf, and G. Folco (2000)
Circulation 101, 1436-1440
   Abstract »    Full Text »    PDF »
Pharmacological Characterization of Leukotriene Receptors.
S.-E. DAHLEN (2000)
Am. J. Respir. Crit. Care Med. 161, S41-45
   Full Text »    PDF »
Leukotrienes in Cardiovascular Diseases.
G. FOLCO, G. ROSSONI, C. BUCCELLATI, F. BERTI, J. MACLOUF, and A. SALA (2000)
Am. J. Respir. Crit. Care Med. 161, S112-116
   Full Text »    PDF »
Getting the Story Right.
T. P. Duffy (1993)
N. Engl. J. Med. 328, 1333-1336
   Full Text »
Leukotrienes and lipoxins: structures, biosynthesis, and biological effects.
B Samuelsson, S. Dahlen, J. Lindgren, C. Rouzer, and C. Serhan (1987)
Science 237, 1171-1176
   Abstract »    PDF »
Intravenous Epinephrine Therapy in Anaphylaxis.
J. H. Levy (1983)
JAMA 249, 3173
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)